{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:24:22Z","timestamp":1771460662349,"version":"3.50.1"},"reference-count":15,"publisher":"Grigore T. Popa University of Medicine and Pharmacy","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Clin Cases"],"abstract":"<jats:p>Burning mouth syndrome is a chronic painful condition characterized by a subjective intraoral pain and burning sensations in the absence of an identifiable medical, dental, or psychiatric cause. Although the underlying etiology is currently unclear, an idiopathic (or primary) form and a secondary form to other conditions are formally recognized. However, as several authors have suggested, it might be of clinical utility to consider the existence of a third clinical entity, namely Drug-Induced Burning mouth syndrome, for its therapeutic implications. The latter has been reported with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, antiretrovirals, anticoagulants, chemotherapy, and drugs commonly used in the treatment of neuropsychiatric disorders such as antidepressants, benzodiazepines, and antipsychotics. Regarding anticonvulsants a literature search found a previous case of Topiramate-Induced Burning mouth syndrome but no previous report of valproate-induced Burning mouth syndrome. Our case is, to date, the first case in the literature of Burning mouth syndrome onset following the administration of valproate to a patient suffering from fibromyalgia and bipolar spectrum disorder. Symptoms resolved completely when the drug was stopped, and the association between symptoms and drug was replicated after drug re-administration.<\/jats:p>","DOI":"10.22551\/2023.40.1003.10257","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T18:02:39Z","timestamp":1698429759000},"page":"125-127","source":"Crossref","is-referenced-by-count":2,"title":["Valproate-induced burning mouth syndrome in a male with fibromyalgia and bipolar spectrum disorder"],"prefix":"10.22551","volume":"10","author":[{"name":"Department of Psychiatry, Unit of Psychiatric Disorders in Medical Complex Pathologies, University of Pisa, Pisa, Italy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-346X","authenticated-orcid":false,"given":"Accursio","family":"Raia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Psychiatry, Unit of Psychiatric Disorders in Medical Complex Pathologies, University of Pisa, Pisa, Italy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2125-0776","authenticated-orcid":false,"given":"Clara","family":"Montalbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Psychiatry, Unit of Psychiatric Disorders in Medical Complex Pathologies, University of Pisa, Pisa, Italy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"9837","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"ref0","unstructured":"\"1. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician. 2002;65(4):615-620. PMID: 11871678."},{"key":"ref1","unstructured":"2. Salort-Llorca C, M\u00ednguez-Serra MP, Silvestre FJ. Drug-induced burning mouth syndrome: a new etiological diagnosis. Med Oral Patol Oral Cir Bucal. 2008;13(3):E167-170. PMID: 18305436."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Feller L, Fourie J, Bouckaert M, et al. Burning Mouth Syndrome: Aetiopathogenesis and Principles of Management. Pain Res Manag. 2017;2017:1926269. doi: 10.1155\/2017\/1926269. PMID: 29180911; PMCID: PMC5664327.","DOI":"10.1155\/2017\/1926269"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Wu S, Zhang W, Yan J, et al. Worldwide prevalence estimates of burning mouth syndrome: A systematic review and meta-analysis. Oral Dis. 2022;28(6):1431-1440. doi: 10.1111\/odi.13868. PMID: 33818878.","DOI":"10.1111\/odi.13868"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Minor JS, Epstein JB. Burning mouth syndrome and secondary oral burning. Otolaryngol Clin North Am. 2011;44(1):205-vii. doi:10.1016\/j.otc.2010.09.008","DOI":"10.1016\/j.otc.2010.09.008"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Fortuna G, Pollio A. Drug-induced burning mouth syndrome: a new clinico-pathological entity? J Headache Pain. 2012;13(8):685-686. doi: 10.1007\/s10194-012-0486-x. PMID: 23054064; PMCID: PMC3484256.","DOI":"10.1007\/s10194-012-0486-x"},{"key":"ref6","unstructured":"7. Salort-Llorca C, M\u00ednguez-Serra MP, Silvestre FJ. Drug-induced burning mouth syndrome: a new etiological diagnosis. Med Oral Patol Oral Cir Bucal. 2008;13(3):E167-170. PMID: 18305436."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Giudice M. Mouths on Fire: Drug-Induced Burning Mouth Syndrome. Can Pharm J\/Rev Pharm Can. 2008;141(2):132-134. doi:10.3821\/1913701X2008141132MOFDBM20CO2","DOI":"10.3821\/1913-701X(2008)141[132:MOFDBM]2.0.CO;2"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Levenson JL. Burning mouth syndrome as a side effect of SSRIs. J Clin Psychiatry. 2003;64(3):336-337; author reply 337-8. doi: 10.4088\/jcp.v64n0317b. PMID: 12716278.","DOI":"10.4088\/JCP.v64n0317b"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Culhane NS, Hodle AD. Burning mouth syndrome after taking clonazepam. Ann Pharmacother. 2001;35(7-8):874-876. doi: 10.1345\/aph.1Z434. PMID: 11485137.","DOI":"10.1345\/aph.1Z434"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Friedman DI. Topirimate-induced burning mouth syndrome. Headache. 2010;50(8):1383-1385. doi: 10.1111\/j.1526-4610.2010.01720.x. PMID: 20561063.","DOI":"10.1111\/j.1526-4610.2010.01720.x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int. 2000;37(2-3):103-110. doi: 10.1016\/s0197-0186(00)00013-9. PMID: 10812195.","DOI":"10.1016\/S0197-0186(00)00013-9"},{"key":"ref12","unstructured":"13. WHO. International drug monitoring: the role of national centres. Tech Rep Ser WHO 1972, no 498."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007;47:513-539. doi: 10.1146\/annurev.pharmtox.47.120505.105150. PMID: 16879083.","DOI":"10.1146\/annurev.pharmtox.47.120505.105150"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223-1244. doi: 10.1111\/j.1528-1167.2007.01041.x. PMID: 17386054. \"","DOI":"10.1111\/j.1528-1167.2007.01041.x"}],"container-title":["Archive of Clinical Cases"],"original-title":[],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T18:04:12Z","timestamp":1698429852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.clinicalcases.eu\/index.php\/acc\/article\/view\/970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,30]]}},"URL":"https:\/\/doi.org\/10.22551\/2023.40.1003.10257","relation":{},"ISSN":["2360-6975","2360-6975"],"issn-type":[{"value":"2360-6975","type":"print"},{"value":"2360-6975","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]}}}